In summary, we provide the first evidence demonstrating that IGF2R is over‐expressed in DMD and mdx muscles and that systemic administration of an anti‐IGF2R‐neutralizing antibody resulted in the recovery of the dystrophic muscle phenotype, ameliorated vascular architecture defects and improved muscle force. The gene discussed is IGF2R; the disease is Duchenne muscular dystrophy.